kw 2189 has been researched along with Liver Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alberts, SR; Camoriano, JK; Pitot, HC; Rubin, J; Suman, VJ | 1 |
1 trial(s) available for kw 2189 and Liver Neoplasms
| Article | Year |
|---|---|
Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Duocarmycins; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pyrrolidinones; Treatment Outcome | 2007 |